Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis C

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 162 articles:
HTML format
Text format



Single Articles


    May 2017
  1. SAXENA V, Khungar V, Verna EC, Levitsky J, et al
    Safety and Efficacy of Current DAA Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Results from the HCV-TARGET Study.
    Hepatology. 2017 May 15. doi: 10.1002/hep.29258.
    PubMed     Text format     Abstract available


  2. GANE EJ, Shiffman ML, Etzkorn K, Morelli G, et al
    Sofosbuvir-velpatasvir with ribavirin for 24 weeks in HCV patients previously treated with a direct-acting antiviral regimen.
    Hepatology. 2017 May 12. doi: 10.1002/hep.29256.
    PubMed     Text format     Abstract available


    April 2017
  3. PEMBROKE T, Sebastiani G
    Hepatic steatosis, hepatitis C and human immunodeficiency viruses: A complex interplay.
    Hepatology. 2017 Apr 19. doi: 10.1002/hep.29218.
    PubMed     Text format    


  4. GUO X, Wang S, Qiu ZG, Dou YL, et al
    Efficient replication of blood borne Hepatitis C Virus in human fetal liver stem cells.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29211.
    PubMed     Text format     Abstract available


  5. ONO A, Goossens N, Finn RS, Schmidt WN, et al
    Persisting risk of hepatocellular carcinoma after HCV cure monitored by a liver transcriptome signature.
    Hepatology. 2017 Apr 8. doi: 10.1002/hep.29203.
    PubMed     Text format    


  6. MERLI M, Frigeni M, Gotti M, Grossi P, et al
    Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas.
    Hepatology. 2017 Apr 5. doi: 10.1002/hep.29198.
    PubMed     Text format    


  7. LAI TS, Lee MH, Yang HI, You SL, et al
    Hepatitis C Viral Load, Genotype, and Increased Risk of Developing End-stage Renal Disease: REVEAL-HCV Study.
    Hepatology. 2017 Apr 2. doi: 10.1002/hep.29192.
    PubMed     Text format     Abstract available


    March 2017
  8. PERRILLO RP
    HBV Reactivation During DAA Treatment of Chronic Hepatitis C: A Hidden Danger of an Otherwise Major Success Story.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29185.
    PubMed     Text format    


  9. SORIA A, Fabbiani M, Lapadula G, Gori A, et al
    Unexpected viral relapses in HCV-infected patients diagnosed with hepatocellular carcinoma during treatment with DAAs.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29181.
    PubMed     Text format    


  10. KIM SJ, Jang JY, Kim EJ, Cho EK, et al
    Ginsenoside Rg3 Restores Hepatitis C Virus-Induced Aberrant Mitochondrial Dynamics and Inhibits Virus Propagation.
    Hepatology. 2017 Mar 22. doi: 10.1002/hep.29177.
    PubMed     Text format     Abstract available


  11. CHANG FM, Wang YP, Lang HC, Tsai CF, et al
    Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: A population-based study.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29172.
    PubMed     Text format     Abstract available


  12. SURAWEERA D, Saab S
    Hepatitis C Treatment Threshold in Patients with Decompensated Liver Disease.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29175.
    PubMed     Text format    


  13. SASAKI R, Devhare PB, Steele R, Ray R, et al
    Hepatitis C virus induced CCL5 secretion from macrophages activates hepatic stellate cells.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29170.
    PubMed     Text format     Abstract available


  14. STELMA F, van der Ree MH, Sinnige MJ, Brown A, et al
    Immune phenotype and function of NK and T cells in chronic hepatitis C patients who received a single dose of anti-miR-122, RG-101.
    Hepatology. 2017 Mar 11. doi: 10.1002/hep.29148.
    PubMed     Text format     Abstract available


  15. HEZODE C, Colombo M, Bourliere M, Spengler U, et al
    Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29139.
    PubMed     Text format     Abstract available


    February 2017
  16. BELPERIO PS, Shahoumian TA, Mole LA, Backus LI, et al
    Evaluation of Hepatitis B Reactivation among 62,920 Veterans treated with Oral Hepatitis C Antivirals.
    Hepatology. 2017 Feb 27. doi: 10.1002/hep.29135.
    PubMed     Text format     Abstract available


  17. YAN F, Wang Y, Zhang W, Chang M, et al
    Human ES Cell-derived Hepatoblasts are an Optimal Lineage Stage for HCV Infection.
    Hepatology. 2017 Feb 25. doi: 10.1002/hep.29134.
    PubMed     Text format     Abstract available


  18. LAWITZ E, Poordad F, Wells J, Hyland RH, et al
    Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in DAA-experienced patients with genotype 1 HCV.
    Hepatology. 2017 Feb 21. doi: 10.1002/hep.29130.
    PubMed     Text format     Abstract available


  19. HOGAN JJ, Lim MA, Palmer MB, Bloom RD, et al
    Development of proteinuria and focal segmental glomerulosclerosis during direct acting antiviral therapy for hepatitis C virus infection (HEP-16-2474.R1).
    Hepatology. 2017 Feb 17. doi: 10.1002/hep.29125.
    PubMed     Text format     Abstract available


  20. SABERI B, Dadabhai AS, Durand CM, Philosophe B, et al
    Challenges in Treatment of Hepatitis C among Patients with Hepatocellular Carcinoma.
    Hepatology. 2017 Feb 17. doi: 10.1002/hep.29126.
    PubMed     Text format    


  21. BRUDEN DJ, McMahon BJ, Townshend-Bulson L, Gounder P, et al
    Risk of End Stage Liver Disease, Hepatocellular Carcinoma and Liver-Related Death By Fibrosis Stage in the Hepatitis C Alaska Cohort.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29115.
    PubMed     Text format     Abstract available


  22. DENOLLY S, Cosset FL
    A master regulator of tight junctions involved in hepatitis C virus entry and pathogenesis.
    Hepatology. 2017 Feb 8. doi: 10.1002/hep.29066.
    PubMed     Text format    


  23. FERNANDEZ CARRILLO C, Lens S, Llop E, Pascasio JM, et al
    Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of MELD: Analysis of data from the Hepa-C registry.
    Hepatology. 2017 Feb 7. doi: 10.1002/hep.29097.
    PubMed     Text format     Abstract available


  24. CARTER L, Aronsohn A
    Overcoming Injustice: A Roadmap to Improve Access to HCV Therapy for Our Medicaid Patients.
    Hepatology. 2017 Feb 4. doi: 10.1002/hep.29095.
    PubMed     Text format    


  25. OLIVEIRA C, Fournier C, Descamps V, Morel V, et al
    Apolipoprotein(a) Inhibits Hepatitis C Virus Entry Through Interaction With Infectious Particles.
    Hepatology. 2017 Feb 2. doi: 10.1002/hep.29096.
    PubMed     Text format     Abstract available


    January 2017
  26. POORDAD F, Felizarta F, Asatryan A, Sulkowski MS, et al
    Glecaprevir and Pibrentasvir for 12 Weeks for HCV Genotype 1 Infection and Prior Direct-acting Antiviral Treatment.
    Hepatology. 2017 Jan 27. doi: 10.1002/hep.29081.
    PubMed     Text format     Abstract available


  27. BERENGUER J, Rodriguez-Castellano E, Carrero A, Von Wichmann MA, et al
    Eradication of HCV and non-liver-related non-AIDS-related events in HIV/HCV coinfection.
    Hepatology. 2017 Jan 21. doi: 10.1002/hep.29071.
    PubMed     Text format     Abstract available


  28. COUSIEN A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, et al
    Reply to "Addressing opioid use disorder in modeling hepatitis C transmission among persons who inject drugs".
    Hepatology. 2017 Jan 21. doi: 10.1002/hep.29069.
    PubMed     Text format    


  29. SMITH J, Rich J
    Addressing opioid use disorder in modeling hepatitis C transmission among persons who inject drugs.
    Hepatology. 2017 Jan 21. doi: 10.1002/hep.29070.
    PubMed     Text format    


  30. O'BRIEN TR, Kottilil S, Feld JJ, Morgan TR, et al
    Race or Genetic Makeup for HCV Treatment Decisions?
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29057.
    PubMed     Text format    


  31. SU F, Ioannou GN
    Reply to: Race or Genetic Makeup for HCV Treatment Decisions?
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29058.
    PubMed     Text format    


  32. VERNA EC
    The Dynamic Landscape of Liver Transplant in the Era of Effective HCV Therapy.
    Hepatology. 2017 Jan 17. doi: 10.1002/hep.29054.
    PubMed     Text format    


  33. ARORA P, Basu A, Schmidt ML, Clark GJ, et al
    NS5B Promotes Degradation of the NORE1A Tumor Suppressor to Facilitate Hepatitis C Virus Replication.
    Hepatology. 2017 Jan 16. doi: 10.1002/hep.29049.
    PubMed     Text format     Abstract available


  34. HEI L, Zhong J
    LGP2 plays an essential role in HCV infection-induced interferon responses.
    Hepatology. 2017 Jan 16. doi: 10.1002/hep.29050.
    PubMed     Text format     Abstract available


    December 2016
  35. KOWDLEY KV, Sundaram V, Jeon CY, Qureshi K, et al
    Eight weeks of Ledipasvir/Sofosbuvir is effective for selected patients with genotype 1 Hepatitis C virus infection.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29005.
    PubMed     Text format     Abstract available


  36. VIETHEER P, Boo I, Gu J, McCaffrey K, et al
    The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28989.
    PubMed     Text format     Abstract available


  37. BALISTRERI WF, Murray KF, Rosenthal P, Bansal S, et al
    The Safety and Effectiveness of Ledipasvir-Sofosbuvir in Adolescents 12 to 17 Years Old With Hepatitis C Virus Genotype 1 Infection.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28995.
    PubMed     Text format     Abstract available


  38. MARTINI S, Salizzoni M, David E, Tandoi F, et al
    Favorable short-term outcome of HCV-positive liver graft with bridging fibrosis: A plea for very early viral eradication.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28978.
    PubMed     Text format     Abstract available


  39. PRICE JC, Ma Y, Scherzer R, Korn N, et al
    HIV-infected and Uninfected Adults with Non-Genotype 3 Hepatitis C Virus Have Less Hepatic Steatosis than Adults with Neither Infection.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28968.
    PubMed     Text format     Abstract available


  40. ARTEMOVA M, Abdurakhmanov D, Ignatova T, Mukhin N, et al
    Persistent HCV-associated Cryoglobulinemic Vasculitis Following Virus Eradication after Direct-Acting Antivirals Therapy.
    Hepatology. 2016 Dec 10. doi: 10.1002/hep.28981.
    PubMed     Text format    


    November 2016
  41. LEVY PL, Duponchel S, Eischeid H, Molle J, et al
    Hepatitis C virus infection triggers a tumor-like glutamine metabolism.
    Hepatology. 2016 Nov 18. doi: 10.1002/hep.28949.
    PubMed     Text format     Abstract available


  42. CHHATWAL J, Samur S, Kues B, Ayer T, et al
    Optimal Timing of Hepatitis C Treatment for Patients on the Liver Transplant Waiting List.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28926.
    PubMed     Text format     Abstract available


    October 2016
  43. SU F, Green PK, Berry K, Ioannou GN, et al
    The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28901.
    PubMed     Text format     Abstract available


  44. LAWITZ E, Poordad F, Gutierrez JA, Wells JT, et al
    Short-duration Treatment With Elbasvir/Grazoprevir and Sofosbuvir for Hepatitis C: A Randomized Trial.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28877.
    PubMed     Text format     Abstract available


  45. BRADY JE, Liffmann DK, Yartel A, Kil N, et al
    Uptake of Hepatitis C Screening, Characteristics of Patients Tested, and Intervention Costs in the BEST-C Study.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28880.
    PubMed     Text format     Abstract available


  46. MAROT A, Vandenbulcke H, Knebel JF, Doerig C, et al
    External validation of the nomogram for individualized prediction of HCC occurrence in patients with HCV-related compensated cirrhosis.
    Hepatology. 2016 Oct 13. doi: 10.1002/hep.28865.
    PubMed     Text format    


    September 2016
  47. KLEPPER A, Eng FJ, Doyle EH, El-Shamy A, et al
    Hepatitis C virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28846.
    PubMed     Text format     Abstract available


  48. WANG RY, Bare P, De Giorgi V, Matsuura K, et al
    Preferential Association of Hepatitis C Virus with CD19+ B Cells Is Mediated by Complement System.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28842.
    PubMed     Text format     Abstract available


  49. KECK ZY, Wang Y, Lau P, Lund G, et al
    Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute HCV infection.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28850.
    PubMed     Text format     Abstract available


  50. ROSEN HR
    "Hep C, where art thou": What are the remaining (fundable) questions in HCV research?
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28848.
    PubMed     Text format    


  51. NISHIO A, Tatsumi T, Nawa T, Suda T, et al
    CD14+ monocyte-derived Galectin-9 induces NK cell cytotoxicity in chronic hepatitis C.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28847.
    PubMed     Text format     Abstract available


  52. MARTINELLO M, Gane E, Hellard M, Sasadeusz J, et al
    Sofosbuvir and ribavirin for six weeks is not effective among people with recent HCV infection: The DARE-C II study.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28844.
    PubMed     Text format     Abstract available


  53. HILL LA, Wyles DL
    Emerging complexities with HCV DAA regimens: Less is still way more.
    Hepatology. 2016 Sep 16. doi: 10.1002/hep.28832.
    PubMed     Text format    


    August 2016
  54. DORE GJ
    Hepatitis C Treatment as Prevention among HIV-infected Men who have Sex with Men: Feasible?
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28784.
    PubMed     Text format    


  55. SALAZAR-VIZCAYA L, Kouyos RD, Zahnd C, Wandeler G, et al
    Hepatitis C virus transmission among HIV-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28769.
    PubMed     Text format     Abstract available


  56. TAWAR RG, Heydmann L, Bach C, Schuttrumpf J, et al
    Broad neutralization of hepatitis C virus resistant variants by Civacir(R) hepatitis C immune globulin.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28767.
    PubMed     Text format     Abstract available


  57. SALLOUM S, Holmes JA, Jindal R, Bale SS, et al
    HIV/HCV in hepatic and stellate cell lines reveals cooperative profibrotic transcriptional activation between viruses and cell types.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28766.
    PubMed     Text format     Abstract available


  58. BANKWITZ D, Pietschmann T
    Hepatitis C virus plays hide and seek with neutralizing antibodies.
    Hepatology. 2016 Aug 12. doi: 10.1002/hep.28760.
    PubMed     Text format    


  59. PAWLOTSKY JM
    The end of the hepatitis C burden: Really?
    Hepatology. 2016 Aug 3. doi: 10.1002/hep.28758.
    PubMed     Text format    


  60. GRAGNANI L, Visentini M, Fognani E, Urraro T, et al
    Prospective Study of Guideline-Tailored Therapy with Direct-Acting Antivirals for Hepatitis C Virus-Associated Mixed Cryoglobulinemia.
    Hepatology. 2016 Aug 2. doi: 10.1002/hep.28753.
    PubMed     Text format     Abstract available


  61. ABE-CHAYAMA H, Hayes CN, Chayama K
    Pan-genotypic cell culture system for propagation of hepatitis c virus clinical isolates.
    Hepatology. 2016 Aug 2. doi: 10.1002/hep.28751.
    PubMed     Text format    


    July 2016
  62. REGAN CP, Morissette P, Regan HK, Travis JJ, et al
    Preclinical Assessment of the Clinical Cardiac Drug-Drug Interaction Associated with the Combination of HCV-NI Antivirals and Amiodarone.
    Hepatology. 2016 Jul 30. doi: 10.1002/hep.28752.
    PubMed     Text format     Abstract available


  63. SUGIYAMA M, Kanto T
    Dual blockade of HCV entry at a gatekeeper of hepatocytes - Not only a preventive but also therapeutic target of CLDN-1.
    Hepatology. 2016 Jul 12. doi: 10.1002/hep.28726.
    PubMed     Text format    


    June 2016
  64. ABERGEL A, Metivier S, Samuel D, Jiang D, et al
    Ledipasvir Plus Sofosbuvir for 12 Weeks in Patients With Hepatitis C Genotype 4 Infection.
    Hepatology. 2016 Jun 28. doi: 10.1002/hep.28706.
    PubMed     Text format     Abstract available


  65. PRENTOE J, Velazquez-Moctezuma R, Foung SK, Law M, et al
    Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.
    Hepatology. 2016 Jun 28. doi: 10.1002/hep.28705.
    PubMed     Text format     Abstract available


  66. GANNE-CARRIE N, Layese R, Bourcier V, Cagnot C, et al
    Nomogram for individualized prediction of hepatocellular carcinoma occurrence in HCV-cirrhosis (ANRS CO12 CirVir).
    Hepatology. 2016 Jun 27. doi: 10.1002/hep.28702.
    PubMed     Text format     Abstract available


  67. ULVELING D, Le Clerc S, Cobat A, Labib T, et al
    A new 3p25 locus is associated with liver fibrosis progression in HIV/HCV co-infected patients.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28695.
    PubMed     Text format     Abstract available


  68. HU KQ, Cui W
    A Highly Specific and Sensitive Hepatitis C Virus Antigens Enzyme Immunoassay for One-step Diagnosis of Viremic HCV Infection.
    Hepatology. 2016 Jun 6. doi: 10.1002/hep.28663.
    PubMed     Text format     Abstract available


    May 2016
  69. MATSUURA K, De Giorgi V, Schechterly C, Wang RY, et al
    Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C.
    Hepatology. 2016 May 26. doi: 10.1002/hep.28660.
    PubMed     Text format     Abstract available


  70. SCHREIBER J, McNally J, Chodavarapu K, Svarovskaia E, et al
    Treatment of a patient with genotype 7 HCV infection with sofosbuvir and velpatasvir.
    Hepatology. 2016 May 14. doi: 10.1002/hep.28636.
    PubMed     Text format    


  71. TOYODA H, Kumada T, Tada T
    Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV.
    Hepatology. 2016 May 2. doi: 10.1002/hep.28632.
    PubMed     Text format    


    April 2016
  72. ASIMAKOPOULOS A, Mangia A, Dore GJ, Lloyd AR, et al
    Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in Europeans.
    Hepatology. 2016 Apr 27. doi: 10.1002/hep.28626.
    PubMed     Text format    


  73. HALFON P, Mohamed S, Penaranda G, Khiri H, et al
    Hepatitis c genotype 4r resistance associated polymorphisms: The achilles heel of the NS5A inhibitors?
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28611.
    PubMed     Text format    


  74. VERLINDEN W, Francque S, Michielsen P, Vanwolleghem T, et al
    Successful antiviral treatment of chronic hepatitis C leads to a rapid decline of liver stiffness without an early effect on spleen stiffness.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28610.
    PubMed     Text format    


  75. FOSCHI A, Casana M, Radice A, Ranieri R, et al
    CORRESPONDENCE: Hepatitis C management in prisons: An insight into daily clinical practice in three major Italian Correctional Houses.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28609.
    PubMed     Text format    


  76. BACKUS LI, Belperio PS, Shahoumian TA, Loomis TP, et al
    Real World Effectiveness of Ledipasvir/Sofosbuvir in 4365 Treatment-Naive Genotype 1 Hepatitis C Infected Patients.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28625.
    PubMed     Text format     Abstract available


  77. MARTIN NK, Vickerman P, Hickman M
    CORRESPONDENCE: HCV testing and treatment in Italian prisons: Implications for prevention benefit and cost-effectiveness.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28612.
    PubMed     Text format    


  78. OZARAS R, Sunbul M, Parlak M, Bodur H, et al
    Treating HBV/HCV Co-infected Patients with Direct Acting HCV Antivirals Only is not Safe.
    Hepatology. 2016 Apr 4. doi: 10.1002/hep.28592.
    PubMed     Text format    


  79. CUBERO FJ
    Shutting off inflammation: A novel switch on hepatic stellate cells.
    Hepatology. 2016;63:1086-9.
    PubMed     Text format    


  80. BARTNECK M, Fech V, Ehling J, Govaere O, et al
    Histidine-rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease.
    Hepatology. 2016;63:1310-24.
    PubMed     Text format     Abstract available


    March 2016
  81. PONZETTO A, Carloni G
    HCV and Lymphoma.
    Hepatology. 2016 Mar 28. doi: 10.1002/hep.28580.
    PubMed     Text format    


  82. SU TH, Chen CL, Kao JH
    RE: HCV and Lymphoma.
    Hepatology. 2016 Mar 28. doi: 10.1002/hep.28578.
    PubMed     Text format    


  83. CHHATWAL J, Wang X, Ayer T, Kabiri M, et al
    Hepatitis C Disease Burden in the United States in the Era of Oral Direct-Acting Antivirals.
    Hepatology. 2016 Mar 25. doi: 10.1002/hep.28571.
    PubMed     Text format     Abstract available


  84. VARGAS H
    Hepatitis C Treatment In 2016: Reasons to be an OPTIMIST.
    Hepatology. 2016 Mar 17. doi: 10.1002/hep.28559.
    PubMed     Text format    


  85. BUTI M, Sanchez-Ruano J, Morillas RM, Esteban R, et al
    Baseline HCV-RNA levels in genotype 1 Chronic Hepatitis C Patients: The role of different cut-off points.
    Hepatology. 2016 Mar 11. doi: 10.1002/hep.28544.
    PubMed     Text format    


  86. PEIFFER KH, Sommer L, Zeuzem S, Sarrazin C, et al
    Reply to the letter to the editor "Interferon Lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in Hepatitis C Virus Genotype 3a".
    Hepatology. 2016 Mar 4. doi: 10.1002/hep.28536.
    PubMed     Text format    


  87. EL-SERAG HB, Kanwal F, Richardson P, Kramer J, et al
    Risk of Hepatocellular Carcinoma after Sustained Virologic Response in Veterans with HCV-infection.
    Hepatology. 2016 Mar 4. doi: 10.1002/hep.28535.
    PubMed     Text format     Abstract available


  88. PEDERGNANA V, Smith D, Klenerman P, Barnes E, et al
    Interferon Lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in Hepatitis C Virus Genotype 3a.
    Hepatology. 2016 Mar 4. doi: 10.1002/hep.28533.
    PubMed     Text format    


  89. HOFFMANN F, Endres S, Rothenfusser S
    Reply.
    Hepatology. 2016;63:1062-3.
    PubMed     Text format    


    February 2016
  90. SIMON TG, Bonilla H, Yan P, Chung RT, et al
    Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and HCC, among patients with HCV Results from ERCHIVES.
    Hepatology. 2016 Feb 18. doi: 10.1002/hep.28506.
    PubMed     Text format     Abstract available


  91. MARTIN NK, Vickerman P, Brew IF, Williamson J, et al
    Is increased HCV case-finding combined with current or 8-12 week DAA therapy cost-effective in UK prisons? A prevention benefit analysis.
    Hepatology. 2016 Feb 10. doi: 10.1002/hep.28497.
    PubMed     Text format     Abstract available


  92. LINDENBACH BD
    "What's next for hepatitis C virus research?"
    Hepatology. 2016 Feb 8. doi: 10.1002/hep.28494.
    PubMed     Text format    


  93. HEZODE C, Chevaliez S, Scoazec G, Soulier A, et al
    Retreatment with sofosbuvir and simeprevir of patients with HCV GT1 or 4 who previously failed a daclatasvir-containing regimen.
    Hepatology. 2016 Feb 8. doi: 10.1002/hep.28491.
    PubMed     Text format     Abstract available


    January 2016
  94. LEROY V, Angus P, Bronowicki JP, Dore GJ, et al
    Daclatasvir, Sofosbuvir, and Ribavirin for Hepatitis C Virus Genotype 3 and Advanced Liver Disease: A Randomized Phase III Study (ALLY-3+).
    Hepatology. 2016 Jan 28. doi: 10.1002/hep.28473.
    PubMed     Text format     Abstract available


  95. SACK J, Garcia-Tsao G
    Variceal hemorrhage in a patient with HCV cirrhosis in whom liver synthetic function had normalized after viral elimination.
    Hepatology. 2016 Jan 25. doi: 10.1002/hep.28470.
    PubMed     Text format    


  96. KWO P, Gitlin N, Nahass R, Bernstein D, et al
    Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in HCV Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study.
    Hepatology. 2016 Jan 22. doi: 10.1002/hep.28467.
    PubMed     Text format     Abstract available


  97. INNES H, Hutchinson SJ, Obel N, Christensen PB, et al
    Liver mortality attributable to chronic hepatitis C virus infection in Denmark and Scotland - using spontaneous resolvers as the benchmark comparator.
    Hepatology. 2016 Jan 16. doi: 10.1002/hep.28458.
    PubMed     Text format     Abstract available


  98. DAHARI H, Cotler SJ, Feld JJ
    Cure prevents more than transmission of HCV.
    Hepatology. 2016 Jan 11. doi: 10.1002/hep.28449.
    PubMed     Text format    


  99. POORDAD F, Schiff ER, Vierling JM, Landis C, et al
    Daclatasvir With Sofosbuvir and Ribavirin for HCV Infection With Advanced Cirrhosis or Post-Liver Transplant Recurrence.
    Hepatology. 2016 Jan 11. doi: 10.1002/hep.28446.
    PubMed     Text format     Abstract available


    December 2015
  100. DESOMBERE I, Fafi-Kremer S, Van Houtte F, Pessaux P, et al
    Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.
    Hepatology. 2015 Dec 28. doi: 10.1002/hep.28428.
    PubMed     Text format     Abstract available


  101. REIN DB, Borton J, Liffmann DK, Wittenborn JS, et al
    The burden of hepatitis C to the United States medicare system in 2009: Descriptive and economic characteristics.
    Hepatology. 2015 Dec 28. doi: 10.1002/hep.28430.
    PubMed     Text format     Abstract available


  102. SAAB S, Park SH, Mizokami M, Omata M, et al
    Safety and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Subjects Aged 65 Years or Older.
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28425.
    PubMed     Text format     Abstract available


  103. LAWITZ E, Matusow G, DeJesus E, Yoshida EM, et al
    Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A Phase 3 study (OPTIMIST-2).
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28422.
    PubMed     Text format     Abstract available


  104. GALMOZZI E
    Do ITPA gene variants provide insight to detecting patients infected with HCV 2/1 recombinant strains?
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28421.
    PubMed     Text format    


  105. WIELAND D, Thimme R
    Vaccine-induced HCV-specific CD8+ T cells do not always help.
    Hepatology. 2015 Dec 10. doi: 10.1002/hep.28388.
    PubMed     Text format    


  106. SU TH, Liu CJ, Tseng TC, Chou SW, et al
    Hepatitis C virus infection increases the risk of lymphoid-neoplasms: A population-based cohort study.
    Hepatology. 2015 Dec 10. doi: 10.1002/hep.28387.
    PubMed     Text format     Abstract available


    November 2015
  107. PISCAGLIA F, Svegliati-Baroni G, Barchetti A, Pecorelli A, et al
    Clinical patterns of hepatocellular carcinoma (hcc) in non alcoholic fatty liver disease (NAFLD): A multicenter prospective study.
    Hepatology. 2015 Nov 24. doi: 10.1002/hep.28368.
    PubMed     Text format     Abstract available


  108. WILDER JM, Jeffers LJ, Ravendhran N, Shiffman ML, et al
    Safety and Efficacy of Ledipasvir-Sofosbuvir in African Americans with Hepatitis C Virus Infection: A Retrospective Analysis of Phase 3 Data.
    Hepatology. 2015 Nov 6. doi: 10.1002/hep.28334.
    PubMed     Text format     Abstract available


  109. HOPCRAFT SE, Evans MJ
    Liver Capsule: HCV Host Cell Entry.
    Hepatology. 2015 Nov 4. doi: 10.1002/hep.28329.
    PubMed     Text format    


  110. CHIDI AP, Rogal S, Bryce CL, Fine MJ, et al
    Cost-Effectiveness of New Antiviral Regimens for Treatment-Naive US Veterans with Hepatitis C.
    Hepatology. 2015 Nov 2. doi: 10.1002/hep.28327.
    PubMed     Text format     Abstract available


    October 2015
  111. BURZA MA, Motta BM, Mancina RM, Pingitore P, et al
    DEPDC5 variants increase fibrosis progression in Europeans with chronic HCV infection.
    Hepatology. 2015 Oct 30. doi: 10.1002/hep.28322.
    PubMed     Text format     Abstract available


  112. CALLENDRET B, Eccleston HB, Satterfield W, Capone S, et al
    Persistent HCV replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and direct acting antiviral.
    Hepatology. 2015 Oct 29. doi: 10.1002/hep.28309.
    PubMed     Text format     Abstract available


  113. BRETT-MAJOR DM, Frick KD, Malia JA, Hakre S, et al
    Costs and consequences: Hepatitis C seroprevalance in the military and its impact on potential screening strategies.
    Hepatology. 2015 Oct 20. doi: 10.1002/hep.28303.
    PubMed     Text format     Abstract available


  114. SISE ME, Bloom AK, Wisocky J, Lin MV, et al
    Treatment of Hepatitis C Virus-Associated Mixed Cryoglobulinemia with Sofosbuvir-Based Direct-Acting Antiviral Agents.
    Hepatology. 2015 Oct 17. doi: 10.1002/hep.28297.
    PubMed     Text format     Abstract available


  115. KELLY C, Swadling L, Capone S, Brown A, et al
    Chronic Hepatitis C Virus infection subverts vaccine induced T-cell immunity in humans.
    Hepatology. 2015 Oct 16. doi: 10.1002/hep.28294.
    PubMed     Text format     Abstract available


  116. O'BRIEN TR, Feld JJ, Kottilil S, Pfeiffer RM, et al
    No Scientific Basis to Restrict 8 Weeks of Treatment with Ledipasvir/Sofosbuvir to Patients with HCV RNA <6,000,000 IU/ml.
    Hepatology. 2015 Oct 16. doi: 10.1002/hep.28292.
    PubMed     Text format    


    September 2015
  117. COLSON P, Borentain P, Dhiver C, Benhaim S, et al
    Recombinant hepatitis C viruses that might hamper accurate genotype classification and choice of treatment with direct-acting agents, southeastern France.
    Hepatology. 2015 Sep 29. doi: 10.1002/hep.28261.
    PubMed     Text format    


  118. PEIFFER KH, Sommer L, Susser S, Vermehren J, et al
    IFN lambda 4 genotypes and resistance-associated variants in HCV genotype 1 and 3 infected patients.
    Hepatology. 2015 Sep 25. doi: 10.1002/hep.28255.
    PubMed     Text format     Abstract available


  119. COUSIEN A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, et al
    Hepatitis c treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs.
    Hepatology. 2015 Sep 21. doi: 10.1002/hep.28227.
    PubMed     Text format     Abstract available


  120. PRIGOZHIN DM, Modis Y
    Flunarizine Arrests Hepatitis C Virus Membrane Fusion.
    Hepatology. 2015 Sep 21. doi: 10.1002/hep.28224.
    PubMed     Text format    


  121. CHUNG RT, Pearson S, Hur C
    Tackling the Hepatitis C Cost Problem: A Test Case for Tomorrow's Cures.
    Hepatology. 2015 Sep 11. doi: 10.1002/hep.28157.
    PubMed     Text format    


    August 2015
  122. SORIANO V, Barreiro P, de Mendoza C
    Hypoglycemia in a diabetic patient during hepatitis C therapy.
    Hepatology. 2015 Aug 27. doi: 10.1002/hep.28137.
    PubMed     Text format    


  123. SIMON TG, Chung RT
    HEP-15-1079: The new HCV bottleneck: can delaying therapy be justified Reply to Letter to the Editor (LTE).
    Hepatology. 2015 Aug 27. doi: 10.1002/hep.28136.
    PubMed     Text format    


  124. CHIRIKOV VV, Shaya F, Mullins CD, dosReis S, et al
    Research is needed on the difficult-to-cure population of HCV patients with disability.
    Hepatology. 2015 Aug 11. doi: 10.1002/hep.28120.
    PubMed     Text format    


  125. KACHKO A, Frey SE, Sirota L, Ray R, et al
    Antibodies to an interfering epitope in hepatitis C Virus E2 can mask vaccine-induced neutralizing activity.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28108.
    PubMed     Text format     Abstract available


  126. WANG H, El Maadidi S, Fischer J, Grabski E, et al
    A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28105.
    PubMed     Text format     Abstract available


  127. TURNER B, Taylor B, Hanson J, Liang Y, et al
    High Priority for Hepatitis C Screening in Safety Net Hospitals: Results from a Prospective Cohort of 4582 Hospitalized Baby Boomers.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28018.
    PubMed     Text format     Abstract available


  128. FUJII Y, Uchida Y, Mochida S
    Reply to the Letter Entitled "Severe Hepatotoxicity Associated with Asunaprevir and Daclatasvir in Chronic Hepatitis C".
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28114.
    PubMed     Text format    


  129. SHIBATA S, Umemura T, Komatsu M, Tanaka E, et al
    Severe hepatotoxicity associated with asunaprevir and daclatasvir in chronic hepatitis C.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28113.
    PubMed     Text format    


  130. PERIN PM, Haid S, Brown RJ, Doerrbecker J, et al
    Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28111.
    PubMed     Text format     Abstract available


  131. FUJITA T, Soontrapa K, Ito Y, Iwaisako K, et al
    Hepatic stellate cells relay inflammation signaling from sinusoids to parenchyma in mouse models of immune-mediated hepatitis.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28112.
    PubMed     Text format     Abstract available


  132. RICE C, Chen Z
    Repurposing an old drug: A low-cost allergy medication provides new hope for hepatitis C patients.
    Hepatology. 2015 Aug 3. doi: 10.1002/hep.28028.
    PubMed     Text format    


  133. KANNINEN TT, Dieterich D, Asciutti S
    HCV vertical transmission in pregnancy: New horizons in the era of DAAs.
    Hepatology. 2015 Aug 3. doi: 10.1002/hep.28032.
    PubMed     Text format     Abstract available


  134. GISH RG, Cohen CA, Block JM, Brosgart CL, et al
    Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States.
    Hepatology. 2015 Aug 3. doi: 10.1002/hep.28026.
    PubMed     Text format    


    July 2015
  135. EDLIN BR, Eckhardt BJ, Shu MA, Holmberg SD, et al
    Towards a more accurate estimate of the prevalence of hepatitis C in the United States.
    Hepatology. 2015 Jul 14. doi: 10.1002/hep.27978.
    PubMed     Text format     Abstract available


  136. KUMADA H, Chayama K, Rodrigues-Jr L, Suzuki F, et al
    Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir for HCV Genotype 1b-infected Japanese Patients With or Without Cirrhosis.
    Hepatology. 2015 Jul 3. doi: 10.1002/hep.27972.
    PubMed     Text format     Abstract available


  137. CARLIN AF, Aristizabal P, Song Q, Wang H, et al
    Temporal dynamics of inflammatory cytokines/chemokines during Sofosbuvir and Ribavirin therapy for Genotype 2 and 3 Hepatitis C infection.
    Hepatology. 2015 Jul 3. doi: 10.1002/hep.27971.
    PubMed     Text format     Abstract available


  138. DE MARTEL C, Maucort-Boulch D, Plummer M, Franceschi S, et al
    Worldwide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma.
    Hepatology. 2015 Jul 3. doi: 10.1002/hep.27969.
    PubMed     Text format     Abstract available


    June 2015
  139. CHAPKO MK, Dufour DR, Hatia R, Drobeniuc J, et al
    Cost-effectiveness of strategies for testing current hepatitis C virus infection.
    Hepatology. 2015 Jun 30. doi: 10.1002/hep.27966.
    PubMed     Text format     Abstract available


  140. PAWLOTSKY JM, Flisiak R, Sarin SK, Rasenack J, et al
    Alisporivir plus ribavirin, interferon-free or in combination with peg-interferon, for HCV genotype 2 or 3 infection.
    Hepatology. 2015 Jun 27. doi: 10.1002/hep.27960.
    PubMed     Text format     Abstract available



  141. Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus.
    Hepatology. 2015 Jun 25. doi: 10.1002/hep.27950.
    PubMed     Text format    


  142. VERGARA C, Thio CL, Thomas D, Duggal P, et al
    Polymorphisms In Melanoma Differentiation-Associated Gene 5 Are Not Associated With Clearance Of Hepatitis C Virus In A European American Population.
    Hepatology. 2015 Jun 23. doi: 10.1002/hep.27954.
    PubMed     Text format    


  143. PEDERGNANA V, Abdel-Hamid M, Guergnon J, Theodorou I, et al
    Refined association of MDA5 variants with spontaneous hepatitis C virus clearance in Egypt.
    Hepatology. 2015 Jun 23. doi: 10.1002/hep.27951.
    PubMed     Text format    


  144. SHLOMAI A
    Hepatitis C virus addiction to liver miR-122 takes its toll on the host.
    Hepatology. 2015 Jun 19. doi: 10.1002/hep.27947.
    PubMed     Text format    


  145. AQEL B, Pungpapong S, Leise M, Werner KT, et al
    Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
    Hepatology. 2015 Jun 11. doi: 10.1002/hep.27937.
    PubMed     Text format     Abstract available


  146. LONTOK E, Harrington P, Howe A, Kieffer T, et al
    Hepatitis C Virus Drug Resistance-associated Substitutions: State of the Art Summary.
    Hepatology. 2015 Jun 10. doi: 10.1002/hep.27934.
    PubMed     Text format     Abstract available


  147. SIMON TG, Chung RT
    The new HCV bottleneck: Can delaying therapy be justified?
    Hepatology. 2015 Jun 8. doi: 10.1002/hep.27931.
    PubMed     Text format    


  148. SAXENA V, Nyberg L, Pauly M, Dasgupta A, et al
    Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C Infected Patients with Compensated and Decompensated Cirrhosis.
    Hepatology. 2015 Jun 1. doi: 10.1002/hep.27922.
    PubMed     Text format     Abstract available


  149. YOUNOSSI ZM, Stepanova M, Marcellin P, Afdhal N, et al
    Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
    Hepatology. 2015;61:1798-808.
    PubMed     Text format     Abstract available


    May 2015
  150. DICK TB, Lindberg LS, Ramirez DD, Charlton MR, et al
    A Clinician's Guide to Drug-Drug Interactions with Direct Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection.
    Hepatology. 2015 May 29. doi: 10.1002/hep.27920.
    PubMed     Text format     Abstract available


  151. TAWAR RG, Colpitts CC, Timm J, Fehm T, et al
    Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties.
    Hepatology. 2015 May 23. doi: 10.1002/hep.27906.
    PubMed     Text format     Abstract available


  152. KUSUMA A, Romero-Brey I, Berger C, Colpitts CC, et al
    Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication via blockage of membranous web formation.
    Hepatology. 2015 May 22. doi: 10.1002/hep.27913.
    PubMed     Text format     Abstract available


  153. LIU Z, Chen T, Wang Y, Zhang M, et al
    Age might confound the impact of the TM6SF2 E167K polymorphism on hepatic fibrosis in HCV- infected patients.
    Hepatology. 2015 May 16. doi: 10.1002/hep.27899.
    PubMed     Text format    


  154. ROMEO S, Aghemo A, Berg T, Stickel F, et al
    TM6SF2 E167K and liver fibrosis in chronic hepatitis C.
    Hepatology. 2015 May 16. doi: 10.1002/hep.27901.
    PubMed     Text format    


  155. CECCHERINI SILBERSTEIN F, Di Maio VC, Aragri M, Ciotti M, et al
    Hepatitis C Virus Gene Sequencing as a Tool for Precise Genotyping in the Era of New Direct Antiviral Agents.
    Hepatology. 2015 May 14. doi: 10.1002/hep.27895.
    PubMed     Text format    


  156. TERRAULT N
    Difficult-to-Cure populations with chronic hepatitis C: Vanishing in the DAA era?
    Hepatology. 2015 May 12. doi: 10.1002/hep.27892.
    PubMed     Text format    


  157. ALQAHTANI SA, Afdhal N, Zeuzem S, Gordon S, et al
    Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hcv genotype 1 infection: Analysis of phase 3 ION trials.
    Hepatology. 2015 May 11. doi: 10.1002/hep.27890.
    PubMed     Text format     Abstract available


  158. YOUNOSSI ZM, Jiang Y, Smith NJ, Stepanova M, et al
    Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States.
    Hepatology. 2015;61:1471-8.
    PubMed     Text format     Abstract available


    April 2015
  159. ABDELRAHMAN T, Hughes J, Main J, McLauchlan J, et al
    Reply.
    Hepatology. 2015;61:1438.
    PubMed     Text format    


    February 2015
  160. TRINCHET JC, Bourcier V, Chaffaut C, Ait Ahmed M, et al
    Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).
    Hepatology. 2015 Feb 11. doi: 10.1002/hep.27743.
    PubMed     Text format     Abstract available


    October 2014
  161. MULLER T, Wiese M, Berg T
    Reply: To PMID 23929603.
    Hepatology. 2014;60:1449-50.
    PubMed     Text format    


  162. MONDELLI MU
    The multifaceted functions of ribavirin: antiviral, immunomodulator, or both?
    Hepatology. 2014;60:1126-9.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: